Novel Urinary Protein Biomarkers Predicting the Development of Microalbuminuria and Renal Function Decline in Type 1 Diabetes
Open Access
- 10 February 2012
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (3), 549-555
- https://doi.org/10.2337/dc11-1491
Abstract
OBJECTIVE: To define a panel of novel protein biomarkers of renal disease. RESEARCH DESIGN AND METHODS: Adults with type 1 diabetes in the Coronary Artery Calcification in Type 1 Diabetes study who were initially free of renal complications (n = 465) were followed for development of micro- or macroalbuminuria (MA) and early renal function decline (ERFD, annual decline in estimated glomerular filtration rate of ≥3.3%). The label-free proteomic discovery phase was conducted in 13 patients who progressed to MA by the 6-year visit and 11 control subjects, and four proteins (Tamm-Horsfall glycoprotein, α-1 acid glycoprotein, clusterin, and progranulin) identified in the discovery phase were measured by enzyme-linked immunosorbent assay in 74 subjects: group A, normal renal function (n = 35); group B, ERFD without MA (n = 15); group C, MA without ERFD (n = 16); and group D, both ERFD and MA (n = 8). RESULTS: In the label-free analysis, a model of progression to MA was built using 252 peptides, yielding an area under the curve (AUC) of 84.7 ± 5.3%. In the validation study, ordinal logistic regression was used to predict development of ERFD, MA, or both. A panel including Tamm-Horsfall glycoprotein (odds ratio 2.9, 95% CI 1.3–6.2, P = 0.008), progranulin (1.9, 0.8–4.5, P = 0.16), clusterin (0.6, 0.3–1.1, P = 0.09), and α-1 acid glycoprotein (1.6, 0.7–3.7, P = 0.27) improved the AUC from 0.841 to 0.889. CONCLUSIONS: A panel of four novel protein biomarkers predicted early renal damage in type 1 diabetes. These findings require further validation in other populations for prediction of renal complications and treatment monitoring.This publication has 40 references indexed in Scilit:
- Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction ruleDiabetologia, 2009
- Urinary Protein Profiles in a Rat Model for Diabetic ComplicationsMolecular & Cellular Proteomics, 2009
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesThe New England Journal of Medicine, 2009
- Multiple loci associated with indices of renal function and chronic kidney diseaseNature Genetics, 2009
- Early nephropathy in type 1 diabetes: the importance of early renal function declineCurrent Opinion in Nephrology and Hypertension, 2009
- Quantitative proteomics and biomarker discovery in human cancerExpert Review of Proteomics, 2009
- Evaluation of Urinary Biomarkers for Coronary Artery Disease, Diabetes, and Diabetic Kidney DiseaseDiabetes Technology & Therapeutics, 2009
- Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes MellitusJAMA Ophthalmology, 2008
- CE‐MS analysis of the human urinary proteome for biomarker discovery and disease diagnosticsProteomics – Clinical Applications, 2008
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006